Janet E Paulsen from 117B Chapin Rd, Hudson, MA 01749, age 69

Us Patents

Modulators Of Gluconeogenesis
view source
US Patent:

7763441, Jul 27, 2010
Filed:

Mar 13, 2007
Appl. No.:

11/717426
Inventors:

Stephen Berasi - Arlington MA, US
Christine Huard - Somerville MA, US
Dongmei Li - Wayland MA, US
Heather Shih - Andover MA, US
Ying Sun - Maynard MA, US
Janet Paulsen - Londonderry NH, US
Eugene L. Brown - Highlands MA, US
Ruth Gimeno - Wellesley MA, US
Robert Martinez - Carlisle MA, US
Assignee:

Wyeth - Madison NJ
International Classification:

C12Q 1/42
C12N 9/16
G01N 33/53
A61K 38/17
US Classification:

435 21, 435196, 435 72, 514 12
Abstract:

The present invention provides methods of affecting gluconeogenesis by altering the levels or activity of DUSP4 and/or EGR1. Pharmaceutical compositions comprising or encoding modulators of gluconeogenesis are also disclosed.

Novel Glutamate Receptor Modulatory Proteins And Nucleic Acid Molecules And Uses Therefor
view source
US Patent:

20020142330, Oct 3, 2002
Filed:

Dec 21, 2001
Appl. No.:

10/027923
Inventors:

Brian Bates - Chelmsford MA, US
Yuhong Xie - Brookline MA, US
Kamalakar Gulukota - Lawrenceville NJ, US
Janet Paulsen - Londonderry NH, US
Assignee:

Genetics Institute, Inc. - Cambridge MA
International Classification:

C12Q001/68
G01N033/53
G06F019/00
G01N033/50
C07H021/04
C12P021/02
C12N005/06
C07K014/705
US Classification:

435/006000, 435/069100, 435/320100, 435/325000, 530/350000, 536/023500, 702/020000
Abstract:

Novel mGluR5M polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length mGluR5M proteins, the invention further provides isolated mGluR5M fusion proteins, antigenic peptides and anti-mGluR5M antibodies. The invention also provides mGluR5M nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which a mGluR5M gene has been introduced or disrupted. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.

Compositions And Methods Of Purifying Myelin-Associated Glycoprotein (Mag)
view source
US Patent:

20060088912, Apr 27, 2006
Filed:

Jul 13, 2005
Appl. No.:

11/180855
Inventors:

Gouying Yan - Lexington MA, US
Yuhong Xie - Chestnut Hill MA, US
Janet Paulsen - Londonderry NH, US
Jimin Zhang - Chestnut Hill MA, US
Dionna Rookey - Philadelphia PA, US
Brian Bates - Chelmsford MA, US
Zhijian Lu - Bedford MA, US
Robert Mark - Lawrenceville NJ, US
Susie Campos - Hackettstown NJ, US
Assignee:

WYETH - Madison NJ
International Classification:

C12P 21/06
C07H 21/04
C12N 5/06
C07K 14/47
US Classification:

435069100, 435455000, 435358000, 530395000, 536023500
Abstract:

The present invention provides compositions and methods useful for purifying recombinant myelin-associated glycoprotein (MAG) and fragments thereof. In particular, the invention provides a one-step purification method for MAG and MAG fragments. Novel forms of human recombinant MAG protein are also disclosed in addition to methods of reliably producing and storing stable recombinant MAG proteins.

Identification Of Adiponutrin-Related Proteins As Esterases And Methods Of Use For The Same
view source
US Patent:

20070014776, Jan 18, 2007
Filed:

Jun 9, 2006
Appl. No.:

11/450935
Inventors:

Ruth Gimeno - Wellesley MA, US
Janet Paulsen - Londonderry NH, US
Jian-Liang Li - Medford MA, US
Andrew Lake - Newton MA, US
Wei Liu - Lexington MA, US
Jae Eun Kim - Waltham MA, US
International Classification:

A61K 38/54
C12Q 1/34
C07H 21/04
C12P 21/06
C12N 9/99
US Classification:

424094200, 435018000, 435069100, 435184000, 435320100, 435325000, 536023200
Abstract:

The present invention provides methods of identifying polypeptides that have enzymatic activity associated with nutrient and/or energy homeostasis, and thus, are involved in the development of one or more cardiovascular and metabolic disorders, e.g., cardiovascular disease, obesity, insulin resistance, type 2 diabetes, dyslipidemia, nonalcoholic fatty liver disease, and metabolic syndrome. One such method comprises identifying a polypeptide as a member of the adiponutrin family of proteins. As such, the invention is related to the polynucleotides and polypeptides belonging to the adiponutrin family, and provides novel isolated and purified polynucleotides and polypeptides of a novel member of the adiponutrin family, patatin-like phospholipase domain 1 (PNPLA1). Also provided are methods of using the polynucleotides and polypeptides related to or provided by the invention for screening a test compound, e.g., a small molecule, antibody, etc., for the ability of the test compound to detect and/or modulate the activity of one or more members of the adiponutrin family of proteins. The present invention also is directed to novel methods for diagnosing, prognosing, and monitoring the progress of at least one cardiovascular and metabolic disorder using polynucleotides or polypeptides belonging to the adiponutrin family, and/or modulators of one or more members of the adiponutrin family. The present invention is further directed to novel therapeutics and therapeutic targets for the intervention (treatment) and prevention of cardiovascular and metabolic disorders arising from dysregulated energy homeostasis, as related to one or more members of the adiponutrin family of proteins.

Compositions And Methods Of Mutant Nogo-66 Domain Proteins
view source
US Patent:

20070026463, Feb 1, 2007
Filed:

Jul 28, 2006
Appl. No.:

11/495061
Inventors:

Yuhong Xie - Chestnut Hill MA, US
Brian Bates - Chelmsford MA, US
Janet Paulsen - Londonderry NH, US
Assignee:

Wyeth - Madison NJ
International Classification:

C40B 30/06
G01N 33/53
C07H 21/04
C12P 21/06
C07K 14/705
US Classification:

435007100, 435069100, 435320100, 435325000, 530350000, 536023500
Abstract:

To facilitate the study of Nogo-66 interaction with its neuronal receptors, and to explore therapeutic opportunities, the present invention provides mutant human Nogo-66 domain-based proteins that do not aggregate during isolation or purification procedures, and methods for using these proteins. Aggregates of Nogo-66 domain containing proteins do not effectively or efficiently bind to the NgR1 receptor, and therefore limit the utility of Nogo-66 domain-based reagents. To overcome aggregation problems, the invention provides proteins that comprise a mutant human Nogo-66 domain, wherein the cysteine at position 47 of the wild-type human Nogo-66 domain is mutated. The invention also provides for various Nogo-66 domain fusion reporter proteins that are able to bind to NgR1, and therefore can be used in high-throughput assays to identify drug candidate compounds that can block binding of the Nogo-66 domain to NgR1, indicating that these compounds may be potential therapeutic agents for neurodegenerative diseases and neuronal repair.

Methods And Compositions For Antagonism Of Rage
view source
US Patent:

20070286858, Dec 13, 2007
Filed:

Mar 21, 2007
Appl. No.:

11/689480
Inventors:

Brian Clancy - Ashland MA, US
Debra Pittman - Windham NH, US
Xiang-Yang Tan - Reading MA, US
Lioudmila Tchistiakova - Andover MA, US
Janet Paulsen - Londonderry NH, US
Angela Widom - Acton MA, US
Nicole Piche-Nicholas - Waltham MA, US
Ying Sun - Maynard MA, US
Assignee:

Wyeth - Madison NJ
International Classification:

A61K 39/395
A61P 19/02
A61P 7/12
C07H 21/04
C07K 16/28
US Classification:

424133100, 424130100, 530387100, 530387300, 530387900, 536023100
Abstract:

Antibodies that bind specifically to receptor for advanced glycation end products (RAGE) and RAGE-binding fragments thereof are disclosed. Also disclosed are pharmaceutical compositions comprising such anti-RAGE antibodies and RAGE-binding antibody fragments thereof, and their use for treatment of RAGE related diseases.

Frazzled Nucleotide Sequences And Expression Products
view source
US Patent:

61657484, Dec 26, 2000
Filed:

Jul 11, 1997
Appl. No.:

8/893654
Inventors:

Lisa Racie - Acton MA
Edward Lavallie - Tewksbury MA
Janet Paulsen - Watertown MA
Hazel Sive - Newton MA
Benjamin Sun - Cambridge MA
Assignee:

Genetics Institute, Inc. - Cambridge MA
Whitehead Institute for Biomedical Research - Cambridge MA
International Classification:

C12N 1510
C12N 1512
C12N 510
C07K 1471
US Classification:

435 691
Abstract:

Purified Frazzled proteins, including WG67-16, WG67-19 and WA628, and processes for producing them are disclosed. DNA molecules encoding the Frazzled proteins, including WG67-16, WG67-19 and WA628, are also disclosed. The proteins may be used in modulating the binding of Wnt genes to their receptor. They are useful in the modulation of cellular formation, growth, differentiation, proliferation and/or maintenance of a variety of adult and embryonic tissues and organs.

Bispecific Antibodies
view source
US Patent:

20200123260, Apr 23, 2020
Filed:

Jun 26, 2019
Appl. No.:

16/453480
Inventors:

- New York NY, US
Lioudmila Tchistiakova - Stoneham MA, US
Kimberly A. Marquette - Somerville MA, US
Janet E. Paulsen - Londonderry NH, US
Ruth E. Gimeno - Carmel IN, US
International Classification:

C07K 16/28
A61P 27/16
C07K 16/24
C07K 16/00
Abstract:

The present invention relates to engineered heteromultimeric proteins, and more specifically, to methods for producing and purifying heterodimeric proteins, such as bispecific antibodies and. Methods for producing and purifying such engineered heterodimeric proteins and their use in diagnostics and therapeutics are also provided. The present invention also relates to a humanized antibody that specifically binds human TrkB and methods for producing and using the antibody to, inter alia, treat a hearing loss disorder.